Recent Finacing
Recent Raise
Braeburn Pharmaceuticals develops CAM2038, a buprenorphine subcutaneous depot in prefilled syringes for HCP-administered once-weekly (8–32 mg) or once-monthly (64–160 mg) OUD treatment.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Braeburn.
